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SUMMARY
Fragile X syndrome (FXS) is the leading genetic
cause of autism. Mutations in Fmr1 (fragile X mental
retardation 1 gene) engender exaggerated transla-
tion resulting in dendritic spine dysmorphogenesis,
synaptic plasticity alterations, and behavioral defi-
cits in mice, which are reminiscent of FXS pheno-
types. Using postmortem brains from FXS patients
and Fmr1 knockout mice (Fmr1/y), we show that
phosphorylation of the mRNA 50 cap binding protein,
eukaryotic initiation factor 4E (eIF4E), is elevated
concomitant with increased expression of matrix
metalloproteinase 9 (MMP-9) protein. Genetic or
pharmacological reduction of eIF4E phosphorylation
rescued core behavioral deficits, synaptic plasticity
alterations, and dendritic spine morphology defects
via reducing exaggerated translation of Mmp9
mRNA in Fmr1/y mice, whereas MMP-9 overexpres-
sion produced several FXS-like phenotypes. These
results uncover a mechanism of regulation of synap-
tic function by translational control of Mmp-9 in FXS,
which opens the possibility of new treatment
avenues for the diverse neurological and psychiatric
aspects of FXS.
INTRODUCTION
Autism spectrum disorders (ASDs) are identified by a cluster of
symptoms in three core domains: social interaction, language,
and range of interests, but in most cases their etiology is un-
known (Elsabbagh et al., 2012). Fragile X syndrome (FXS) is char-
acterized by core deficits in intellectual function, hyperarousal
and anxiety, repetitive behaviors, and morphological abnormal-
ities and has a known genetic cause. Many CGG repeats in
the FMR1 gene induce its hypermethylation, transcriptional
silencing, and loss of fragile X mental retardation protein
(FMRP) expression (Verkerk et al., 1991; Hagerman and Hager-
man, 2013). A large percentage of individuals with FXS (46%)
are codiagnosed with ASD (Budimirovic and Kaufmann, 2011).
Importantly, FXS is the leading known genetic cause of autism.
FMRP is an RNA-binding protein and binds to several ASD-
linked mRNAs (Ascano et al., 2012; Darnell et al., 2011) and re-
presses their translation (Darnell et al., 2011). According to the
metabotropic glutamate receptor (mGluR) theory of FXS, loss
of FMRP expression in FXS induces exaggerated translation of
synaptic plasticity-related mRNAs, downstream of group I
mGluR activation (Bear et al., 2004). This mechanism is best
demonstrated in Fmr1/y mice (Fmr1 deletion on the X chromo-
some), which display enhanced rates of translation, aberrant
spine morphology (increased numbers of long, thin dendritic
spines, which are typical of immature synapses and are also
observed in FXS patients) (McKinney et al., 2005; Rudelli et al.,
1985), defects in synaptic plasticity (enhanced protein synthe-
sis-dependent mGluR long-term depression [LTD]) (Huber
et al., 2001), and morphological/anatomical alterations reminis-
cent of FXS patients (macroorchidism) (The Dutch-Belgian Frag-
ile X Consortium, 1994; Sutherland and Ashforth, 1979).
The translational inhibitory activity of FMRP is regulated pri-
marily by two intracellular signaling cascades known to couple
mGluRs to the translational machinery: the PI3K/Akt/mammalian
target of rapamycin (mTOR) (Sharma et al., 2010) and the Ras/
ERK (extracellular signal-regulated kinase)/Mnk (mitogen-acti-
vated protein kinase interacting kinases) (Osterweil et al.,
2010). These pathways stimulate cap-dependent translation by
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controlling the phosphorylation of translation initiation factors.
mTOR phosphorylates 4E-BPs (eukaryotic Initiation Factor 4E-
Binding Proteins, which are inhibitors of eIF4E) and S6Ks (ribo-
somal protein S6 Kinases) to promote translation initiation (Hay
and Sonenberg, 2004). Genetic deletion of 4E-BP2 (Gkogkas
et al., 2013) or overexpression of eIF4E (Santini et al., 2013)
engenders autism-like behaviors and synaptic plasticity deficits
in mice. Genetic removal of S6K1 corrected molecular, synaptic,
and behavioral deficits in Fmr1/y mice (Bhattacharya et al.,
2012). Moreover, deletion of CPEB1 (cytoplasmic polyade-
nylation element binding protein 1), an activator of translation,
ameliorated biochemical, morphological, electrophysiolo-
gical, and behavioral phenotypes in Fmr1/y mice (Udagawa
et al., 2013).
The Ras/ERK/Mnk pathway stimulates translation largely via
phosphorylation of eIF4E on Ser209 byMnk1 andMnk2 (Waskie-
wicz et al., 1997). Phospho-eIF4E has been implicated in the
regulation of long-lasting forms of synaptic plasticity and mem-
ory (Kelleher et al., 2004). ERK inhibition blocks neuronal activ-
ity-induced translation as well as phosphorylation of eIF4E (Kel-
leher et al., 2004), whereas NMDA receptor activation stimulates
the activity of ERK/Mnk and elicits eIF4E phosphorylation (Banko
et al., 2004). However, how eIF4E phosphorylation promotes
synaptic plasticity andmemory and its role in FXS are not known.
Previously, we studied the role of eIF4E phosphorylation in
tumorigenesis and prostate cancer progression using a knockin
mouse model, where the single phosphorylation site on eIF4E
was mutated (Ser209Ala) (Furic et al., 2010). Genome-wide
translational profiling in mouse embryonic fibroblasts (MEFs) re-
vealed a subset of mRNAs whose translation was reduced in the
Eif4eki (Ser209Ala) mice (Furic et al., 2010). Translation ofMmp9
mRNA and several additional members of the family of Matrix
Metalloproteinases (MMPs) is regulated by eIF4E phosphoryla-
tion in MEFs (Furic et al., 2010). Mmp-9 is a gelatinase, which
is synthesized as a proprotein, secreted, and activated through
cleaving and proteolyzes several components of the extracel-
lular matrix (Huntley, 2012).Mmp-9 plays important roles in spine
morphology, synaptic plasticity, and learning andmemory (Hunt-
ley, 2012).
FMRP inhibits dendritic translation of Mmp9 mRNA (Janusz
et al., 2013); however, the mechanism of this regulation has
not been studied. Mmp-9 has been implicated in FXS and
ASD. High plasma activity of MMP-9 was reported in individ-
uals with FXS (Dziembowska et al., 2013; Leigh et al., 2013),
whereas elevated protein amounts of MMP-9 were detected
in amniotic fluid from ASD mothers (Abdallah et al., 2012). Min-
ocycline, a tetracycline derivative, reduced Mmp-9 protein
amounts in Fmr1/y mice and improved behavioral and den-
dritic spine defects (Bilousova et al., 2009; Dansie et al.,
2013; Rotschafer et al., 2012). However, minocycline is a
broad-spectrum antibiotic targeting several signaling pathways
and showing bacteriostatic and immune suppressing activities.
Thus, it is imperative to know the causality of MMPs in ASD or
FXS and the mechanism leading to increased MMP-9 expres-
sion in FXS.
Here, we show that eIF4E phosphorylation is increased in
FXS patients’ postmortem brains, accompanied by augmented
MMP-9 expression, whereas MMP-9 overexpression in mice
induces phenotypes reminiscent of FXS. We demonstrate
that translation of Mmp9 mRNA is increased due to elevated
eIF4E phosphorylation in Fmr1/y mice. Moreover, genetic
reduction of phospho-eIF4E rescues aberrant Mmp9 mRNA
translation and reverses morphological, synaptic, and behav-
ioral deficits in Fmr1/y mice. Pharmacological inhibition of
eIF4E phosphorylation by cercosporamide, a potent inhibitor
of Mnk kinases (Konicek et al., 2011), reproduces the morpho-
logical, synaptic, and behavioral rescue in Fmr1/y mice. Thus,
translational control of Mmp9 mRNA in response to Mnk-
mediated phosphorylation of eIF4E is a mechanism down-
stream of group 1 mGluRs, which is dysregulated in FXS
(Figure S1).
RESULTS
Elevated Phosphorylation of eIF4E and MMP-9 Protein
Amounts in FXS Patients and Fmr1/y Mice
To investigate whether eIF4E phosphorylation and MMP-9
expression are altered in FXS, we used postmortem brain sam-
ples from FXS patients and age-matched controls. Immunoblot
analysis of frontal cortex and hippocampal samples from FXS
patients using a phospho-eIF4E (Ser 209) antibody revealed a
37.3% ± 2.8% increase in p-eIF4E levels, accompanied by a
42.7% ± 3.2% increase in MMP-9 protein amounts, as
compared to control individuals (Figures 1A and 1B; Figures
S2A and S2B). The increase in p-eIF4E and Mmp-9 protein
amounts was recapitulated in Fmr1/y mice (Figures 1C and
1D); p-eIF4E levels were increased by 67.1% ± 3.4% and
Mmp-9 by 41.1% ± 4.1%, as compared to wild-type mice (Fig-
ures 1C and 1D). Using immunohistochemistry, we observed
increased p-eIF4E in the cortex, thalamus, and hippocampus
of the Fmr1/y mice (Figures 1E and 1F; Figure S2C). Taken
together, these data reveal increased eIF4E phosphorylation
and Mmp-9 protein amounts in the brains of FXS patients and
Fmr1/y mice.
MMP-9 Overexpression Engenders Autism/FXS-like
Phenotypes
Because Mmp-9 is linked to FXS and ASD (Bilousova et al.,
2009), we asked whether MMP-9 overexpression would
engender FXS-like phenotypes in mice. To this end, we used
transgenic (Tg) mice expressing human pro-MMP-9 under the
control of the PDGF-B promoter (Fragkouli et al., 2012),
mimicking the increase of MMP-9 in FXS patients and Fmr1/y
mice (Fragkouli et al., 2012; Figure 1). In MMP9-Tg mice, there
is an increase in both the latent (pro-) and proteolytically acti-
vated forms of MMP-9 (Fragkouli et al., 2012), which is equiva-
lent to the increase observed in Fmr1/y mice (Figures 1C and
S2D). To assess whether MMP-9 overexpression causes social
behavior deficits, as observed in the Fmr1/ymice, we subjected
the MMP9-Tg mice to the three-chamber social interaction test
(Silverman et al., 2010). Social approach behavior was impaired
inMMP9-Tg mice, because they failed to show a preference for
the social (stranger 1) versus the nonsocial stimulus (empty wire
cage; p > 0.05, Figure 2A), as compared to wild-type littermates.
As expected, MMP9-Tg mice were also impaired in the
subsequent three-chamber preference for social novelty test
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(Figure 2A). We then examined theMMP9-Tg mice for repetitive/
stereotyped behaviors, which are a hallmark of FXS patients and
Fmr1/y mice (Bhattacharya et al., 2012), using the self-groom-
ing test. MMP9-Tg mice spent significantly more time
(106.8% ± 8.4%) grooming than their wild-type littermates,
whereas no significant differences were observed in the duration
of each grooming bout (Figure 2B).
FXS patients have increased density of immature (filopodial
type) dendritic spines (Rudelli et al., 1985). This phenotype is
recapitulated in Fmr1/y mice (McKinney et al., 2005). Using
Golgi-Cox staining in MMP9-Tg mice, we found increased
density of dendritic spines in CA1 hippocampal area
(45.2% ± 4.1%), along with a decreased number of mature
(54.3% ± 2.4%; stubby and mushroom type) and increased
number of immature (57.8% ± 2.1%) spines, as compared to
wild-type littermates (Figures 2C–2E). Macroorchidism is
commonly diagnosed in FXS patients (Sutherland and Ash-
forth, 1979) and is also observed in Fmr1/y mice (Bhatta-
charya et al., 2012). Testes from MMP9-Tg mice at postnatal
days 90–100 weighed significantly more (55.4% ± 0.8%, Fig-
ure 2F), as compared to wild-type littermates. Taken together,
these data demonstrate that overexpression of MMP-9 engen-
ders phenotypes similar to those observed in Fmr1/y mice,
such as social deficits, repetitive/stereotyped behaviors, and
abnormalities in dendritic spine morphology, indicating that
increased MMP-9 protein amounts may substantially con-
tribute to FXS pathophysiology.
Exaggerated Mmp9 mRNA Translation in Fmr1/y Mice
Is Alleviated by Genetic Inhibition of eIF4E
Phosphorylation
We hypothesized that exaggerated translation in Fmr1/y mice
could be rescued by genetically reducing eIF4E phosphoryla-
tion, which is a major effector of the hyperactivated Ras/
MAPK/Mnk signaling pathway (Buxade et al., 2008). Importantly,
Mmp9 mRNA is translationally controlled by FMRP at the syn-
apse (Ascano et al., 2012; Darnell et al., 2011; Janusz et al.,
2013). We reported that Mmp9 mRNA is translationally
controlled by eIF4E phosphorylation in fibroblasts (Furic et al.,
2010). Thus, we sought to investigate whether in the brain
the translation of Mmp9 mRNA is regulated by eIF4E
phosphorylation.
We crossed Fmr1/y mice with Eif4eki/ki (knockin; Ser209-
Ala) mice (Eif4eki) or with the Mnk1+//Mnk2+/ heterozygote
mice (Mnkhet) to generate ‘‘double-mutant’’ mice (Figure 3A).
To assess the effect of the genetic reduction of eIF4E phos-
phorylation on protein synthesis, we measured de novo pro-
tein synthesis in hippocampal slices using puromycin labeling,
to tag nascent polypeptide chains (Bhattacharya et al., 2012;
Graber et al., 2013; Schmidt et al., 2009). Although we did
not detect any significant changes in puromycin incorporation
in Eif4eki and Mnkhet slices (Figure S3A), Fmr1/y hippo-
campal slices incorporated significantly more puromycin
(55.3% ± 6.9%), as compared to slices from wild-type mice
(Figure 3B), indicating enhanced translation. Puromycin
A B C D
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Figure 1. Elevated Phosphorylation of eIF4E
and Increased Expression ofMMP-9 in Post-
mortem Brains from FXS Patients and in
Fmr1/y Mouse Brain
(A) Western blot analysis of lysates from frontal
cortex or hippocampus from control ‘‘C’’ (n =
9) and FXS patients ‘‘FXS’’ (n = 8; see Fig-
ure S2). Representative images of immunoblots
probed with antibodies against the indicated
proteins are shown. HSC70 was the loading
control.
(B) Quantification of western blots from (A).
Protein amounts of phospho-eIF4E and MMP9
are normalized to total eIF4E and HSC70 (n = 3
for each group) and presented as fold change
relative to control.
(C) Western blot analysis of whole-brain lysates
from Fmr1/y and wild-type (WT) littermates
(n = 3 for each group). Representative images
of immunoblots probed with antibodies against
the indicated proteins are shown; b-tubulin was
the loading control.
(D) Quantification of data in (C) for phopsho-
eIF4E and Mmp9 protein amounts (n = 3 for
each group), normalized to eIF4E and b-tubulin,
respectively, and presented as fold change
relative to WT.
(E) Immunohistochemical DAB staining of
cortical (CTX.), hippocampal (HIPP.), and thal-
amic (THAL.) 50 mm slices from WT and Fmr1/y mice. Representative images of slices stained with antibodies against the indicated proteins are
shown.
(F) Quantification of immunohistochemical staining in (E) for phopsho-eIF4E (n = 3 for each group; fold change relative to WT). For (A)–(F), Student’s t test,
*p < 0.05. See also Figure S2.
Data are presented as mean ± SEM (error bars).
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incorporation was significantly reduced in both Fmr1/y/Eif4eki
and Fmr1/y/Mnkhet slices, as compared to Fmr1/y slices,
thus demonstrating restoration of protein synthesis, as a
result of the reduction in eIF4E phosphorylation (Figures 3B
and 3C).
Next, we investigated the effect of reduction of eIF4E phos-
phorylation in Fmr1/y mice on specific mRNAs. FMRP inhibits
the translation of a subset of mRNAs (Ascano et al., 2012;
Darnell et al., 2011), either directly through binding to ribo-
some (Chen et al., 2014) or indirectly by regulating signaling
downstream of group 1 mGluRs, impinging upon translation
and transcription. We carried out polysome profiling of hippo-
campal lysates from the four different mouse genotypes
examined for global protein synthesis (Figure 3B). No signifi-
cant changes were detected between the different genotypes
in the overall sedimentation profiles of hippocampal tissue
(Figure 3D), albeit there was a trend for enhanced association
of mRNAs with polysomes in the Fmr1/y mice, when
compared to the other genotypes, as evidenced by the Poly-
somes/Monosome ratio (Figure S3B). Quantitative RT-PCR
(qRT-PCR) analysis of the sucrose density gradient fractions
revealed that in accordance with the data in fibroblasts (Furic
et al., 2010), Mmp9 mRNA is associated with lighter polysome
fractions in Eif4eki and Mnkhet mice, as compared to wild-type
(WT) mice (Figures S3C and S3D), demonstrating that Mmp9
mRNA translation is promoted by eIF4E phosphorylation in
the brain. Conversely, Mmp9 mRNA cosediments with heavier
polysome fractions in Fmr1/y, as compared to wild-type mice
(Figure 3F), indicative of Mmp9 mRNA enhanced translation in
the brain of Fmr1/y mice. It is therefore predicted that in the
‘‘double-mutant’’ strains, Mmp9 mRNA translation would be
restored to wild-type levels, as a result of reduced eIF4E
phosphorylation. Indeed, in Fmr1/y/Eif4eki and Fmr1/y/Mnkhet
mice, Mmp9 mRNA distribution is indistinguishable from wild-
type mice (Figure 3F). This is also reflected in the amounts of
Mmp9 (Figures 3G and 3H). Importantly, because we did not
observe any changes in total Mmp9 mRNA amounts (Fig-
ure 3E) between the different genotypes, increased Mmp9
protein expression detected in Fmr1/y mice (Figures 1C,
1D, 3G, and 3H) can be explained by increased translation
of the Mmp9 mRNA.
Next, we asked whether translation of other known FMRP
target mRNAs, whose expression is enhanced in Fmr1/y
mice, is also regulated via eIF4E phosphorylation. We
observed reversal of the enhanced translation of mRNAs en-
coding additional members of the Mmp family: Mmp2,
Mmp3, Mmp7, and Mmp24 and of Dlg4 (PSD-95) mRNAs (Fig-
ures S3D and S3E). Notably, decreased eIF4E phosphorylation
had no effect on the translation of other known FMRP target
mRNAs, such as Map1b, Shank1, Shank2, Shank3, Nr2, and
Camk2a (Figures S3D, S3F, and S3G). Taken together, these
data demonstrate that genetic reduction of eIF4E phosphoryla-
tion negates the exaggerated translation of Mmp9 mRNA in
Fmr1/y mice by attenuating the hyperactivated Ras/MAPK/
Mnk signaling, thus restoring normal rates of translation in
Fmr1/y mice.
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Figure 2. MMP9-Tg-Overexpressing Mice
Display Autism/FXS-like Phenotypes
(A) Three-chamber social interaction test, showing
time spent in each chamber (top left) and time
spent sniffing each wire cage (top right); S1,
stranger 1 (social stimulus); C, center compart-
ment; E, empty wire-cage compartment (nonso-
cial stimulus). Preference for social novelty three-
chamber social interaction test, showing time
spent in eachchamber (bottom left) and timespent
interacting with the novel social stimulus (bottom
right; stranger 2; S2) or the previously encountered
mouse (stranger 1; S1); C, center compartment.
n = 14 for each group; ***p < 0.001, *p < 0.05, two-
way ANOVA with Bonferroni’s post hoc.
(B) Self-grooming test, where the total time spent
grooming is depicted; n = 14 per group
(C) Golgi-Cox staining of hippocampal CA1 den-
dritic spines from WT and MMP9-Tg mice.
Representative images are shown.
(D) Quantification of spine density (spines per
10 mm) from images in (C).
(E) Spine subtype analysis (S/M, spiny/mushroom;
F, filopodial) presented as a fraction of total spines
for each subtype. ***p < 0.001, two-way ANOVA
with Bonferroni’s post hoc.
(F) Mean testicular weight (mg) of WT andMMP9-
Tg P90-100 mice; n = 12 per group, ***p < 0.001;
Student’s t test. WT, wild-type; MMP9-Tg, litter-
mates overexpressing MMP9.
Data are presented as mean ± SEM (error bars).
For (B) and (D), n = 5 per group,***p < 0.001,
Student’s t test.
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Genetic Reduction of eIF4E Phosphorylation Reverses
Aberrant Dendritic Spine Morphology, Excessive LTD,
and FXS-like Behavioral Phenotypes in Fmr1/y Mice
Having determined that MMP-9 overexpression in mice induces
phenotypes that are commonly observed in Fmr1/y mice (Fig-
ure 2), and that genetic reduction of eIF4E phosphorylation de-
creases translation of Mmp9 mRNA in Fmr1/y mice (Figure 3),
we investigated whether genetic reduction of eIF4E phosphory-
lation would rescue abnormalities in dendritic spinemorphology,
synaptic plasticity, and behavioral deficits in Fmr1/y mice (Fig-
ure 4A). Using Golgi-Cox staining in hippocampal CA1 slices
from the different mouse genotypes, we observed a decrease
in the number of immature and an increase in the number of
mature spines in both Fmr1/y/Eif4Eki and Fmr1/y/Mnkhet
A B C
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Figure 3. Phospho-eIF4E-Dependent Translation of Mmp9 in FXS Model Mice
(A) Breeding scheme to acquire ‘‘double-mutant’’ mice, where eIF4E phosphorylation is depleted (Fmr1/y/Eif4eki) or significantly reduced (Fmr1/y/Mnkhet).
(B) Puromycin incorporation assay in the four genotypes examined: WT, Fmr1/y, Fmr1/y/Eif4eki, and Fmr1/y/Mnkhet. Puromycin-labeled CA1 hippocampal
slices were lysed and subjected to immunoblotting; representative images of immunoblots are shown, probed with antibodies against the indicated proteins;
b-tubulin was the loading control.
(C) Quantification of the puromycin incorporation assay in (B). Puromycin incorporation (puromycin antibody signal intensity) was normalized to the loading
control and presented as percentage change relative to WT; n = 3, *p < 0.05, Student’s t test.
(D) Polysome profiling in hippocampal lysates from the four indicated genotypes. Positions of the 80S ribosome peak and polysomes are indicated.
(E) Total mRNA amounts for Mmp9 and Actb assessed by qRT-PCR in the four indicated genotypes.
(F) qRT-PCR on RNA extracted from polysome fractions. Distribution of indicated mRNAs is illustrated as relative mRNA amounts for the different fractions and
normalized between different fractions to control; n = 4, Student’s t test.
(G) Representative immunoblots from hippocampal lysates for the four indicated genotypes, probed with antibodies against the indicated proteins; b-actin was
the loading control.
(H) Quantification of immunoblots from (G); n = 4, Mmp-9 protein amounts are normalized to b-actin. *p < 0.05 Student’s t test. See also Figure S3.
Data are presented as mean ± SEM (error bars).
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mice, as compared to the Fmr1/y mice (Figures 4B and 4C),
which restores the dendritic spine phenotype to wild-type levels.
On the other hand, we did not observe any significant changes in
CA1 dendritic morphology in Eif4eki or Mnkhet mice, when
compared to wild-type mice (Figure S4A).
Elevated translation in Fmr1/ymice leads to enhanced hippo-
campal mGluR-LTD (Huber et al., 2001). Consistent with these
findings, stimulation of group 1-metabotropic glutamate recep-
tors led to enhanced mGluR-LTD in Fmr1/y hippocampal slices
(Figure 4D). In contrast, mGluR-LTD in hippocampal slices from
Eif4eki andMnkhet micewas not significantly different from that of
wild-type mice (Figure S4B). Input/output curves and paired
pulse ratio were also unaffected in Eif4eki and Mnkhet, as
compared to wild-type mice (Figures S5A and S5B). In slices
from Fmr1/y/Eif4eki and Fmr1/y/Mnkhet mice, mGluR-LTD
was comparable to that from WT slices and significantly lower
than in Fmr1/y slices (Figures 4D and 4E).
Next, we explored the effects of eIF4E phosphorylation on
FXS-like behaviors. We first subjected mice to the three-cham-
ber preference for social novelty test. In agreement with previous
reports (Bhattacharya et al., 2012), we noted an impaired prefer-
ence for social novelty in the Fmr1/y mice, whereas WT mice
clearly show a preference for the novel social stimulus (stranger
2), as compared to the original social stimulus (stranger 1; Fig-
ure 4F). In the ‘‘double mutants,’’ reducing eIF4E phosphoryla-
tion rescued the impairment in the preference for social novelty
test, as compared to Fmr1/y mice (Figure 4F). To further inves-
tigate the reversal of the social behavior impairment, we carried
out direct social interaction tests with a juvenile (Figure 4G) or a
female mouse (Figure 4H). During the interaction with a juvenile
male, Fmr1/y mice displayed aggressive behavior (shorter
latency to attack; Figure 4G), but not significant changes in social
interaction (time in affiliation; Figure 4G), as compared to wild-
type littermates. When an Fmr1/y male interacted with a female
mouse, it displayed repetitive behavior, engaging in increased
duration of self-grooming, and demonstrated reduced male-
female affiliation time (Figure 4H). These data are consistent
with previous reports for Fmr1 knockout in the C57BL/6 back-
ground (Bhattacharya et al., 2012). In the ‘‘double mutants,’’
where eIF4E phosphorylation is reduced, there was a complete
rescue of the aggressive behavior while interacting with a juve-
nile mouse (Figure 4G), partial rescue of the repetitive, excessive
grooming, and complete rescue of the reduced affiliation while
interacting with a female (Figure 4H), as compared to wild-type
mice. Yet, in Eif4eki and Mnkhet mice, there were no significant
behavioral changes in the direct social interaction tests with a
juvenile male or a female (Figure S4D). Conversely, Eif4eki and
Mnkhet mice display impaired preference for social novelty, as
compared to wild-type mice (Figure S4C). This shows that the
rescues are specific.
Hyperactivity, seizures, and epilepsy are common symptoms
in FXS, which are also exhibited by Fmr1/y mice (Musumeci
et al., 2007; Spencer et al., 2005). To assess hyperactivity, we
performed the light-dark transition (Figure 4I) and open-field
tests (Figure 4J). Fmr1/y mice are significantly more active
than wild-type littermates as depicted by the number of light-
dark compartment transitions (Figure 4I) and the number of en-
tries and time spent in the center square of the open-field arena
(Figure 4J). The ‘‘double mutants’’ showed reversal of hyperac-
tivity/anxiety-like phenotypes in the light-dark and open-field
tests (Figures 4I and 4J). We then proceeded to examine the
effect of reduced eIF4E phosphorylation on audiogenic seizure
susceptibility (AGS), which is age dependent (peak sensitivity
at P21). C57Bl/6 mice are resistant to AGS (Seyfried et al.,
1980). Fmr1/y mice displayed increased tonic-clonic seizures,
and respiratory arrest or death (Figure 4K). The ‘‘double mu-
tants’’ were resistant to the induction of AGS, with only a small
number of animals (25%) displaying AGS. On the other hand,
Eif4eki and Mnkhet mice behavior was comparable to wild-type
animals in the light-dark, open-field, and AGS tests (Figure S4E;
Eif4eki and Mnkhet are resistant to AGS, similar to wild-type).
Because MMP-9 overexpression led to a macroorchidism
phenotype, we examined whether inhibition of eIF4E phosphor-
ylation (and thus reduced translation of Mmp9 mRNA) would
rescue this FXS-like phenotype. Indeed, ‘‘double-mutant’’ mice
display a significant decrease in testicular weight when
compared to Fmr1/ymice, which constitutes a complete rescue
of the macroorchidism phenotype when compared to wild-type
mice (Figure S4F). We did not observe any rescue in the novel
object recognition or the rotarod (motor coordination) tests
(Figures S4G and S4H). However, in these tests, Fmr1/y mice
displayed significant impairments in accordance with previous
Figure 4. Genetic Reduction of eIF4E Phosphorylation Rescues FXS-like Phenotypes
(A) Haploinsufficiency of Mnk1 and Mnk2 or alanine mutation of Ser209 in eIF4E inhibits eIF4E phosphorylation in mice.
(B) Golgi-Cox staining of CA1 dendritic spines in four genotypes: WT, Fmr1/y, Fmr1/y/Eif4eki, and Fmr1/y/Mnkhet.
(C) Quantification of spine analysis for (B). Spine density for the four indicated phenotypes is measured as the number of spines per 10 mm; n = 5 per group,***p <
0.001, Student’s t test. Spine subtype analysis (S/M, spiny/mushroom; F, filopodial), presented as a fraction of total spines for each subtype; n = 5 per group,
***p < 0.001, two-way ANOVA with Bonferroni’s post hoc.
(D) mGluR-LTD was induced with DHPG (50 mM for 10 min) in hippocampal slices prepared from mice of the four indicated genotypes.
(E) Summary bar graph showing mGluR-LTD at 110–120 min period postinduction. Scale bar, 5 ms and 1 mV. *p < 0.05, **p < 0.01, one-way ANOVA with
Bonferroni’s post hoc. (n = WT [14], Fmr1/y [25], Fmr1/y/Eif4eki [16], Fmr1/y/Mnkhet [16].) See also Figure S4B.
(F) Preference for social novelty three-chamber social interaction test, showing time spent in each chamber (LEFT) and time spent interacting with the novel social
stimulus (right; stranger 2; S2) or the previously encountered mouse (stranger 1; S1); C, center compartment.
(G) Social interaction with a juvenile male mouse test. Latency to attack and time spent in affiliation are measured for the indicated genotypes.
(H) Social interaction with a female mouse test. Time engaged in self-grooming and time spent in affiliation are measured for the indicated genotypes.
(I) Light-dark transition test. Number of transitions between the light and dark compartments is depicted for the indicated genotypes.
(J) Open-field exploration. Number of entries and time spent in the center square of an open field is measured for the four genotypes.
(K) Audiogenic seizure frequency (percentage of animals having seizures) for the indicated genotypes. X marks resistance of WT mice to AGS.
For (F)–(K), n = 14 for each group; ***p < 0.001, *p < 0.05, two-way ANOVA with Bonferroni’s post hoc. See also Figure S4. Data are presented as mean ± SEM
(error bars).
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reports (Bhattacharya et al., 2012), whereas Eif4eki and Mnkhet
mice performed similarly to wild-type (Figures S4G and S4H).
Additionally, we confirmed that the rescue effect was not
male specific because also in female Fmr1/ mice genetic
reduction of eIF4E phosphorylation corrected impaired prefer-
ence for social novelty (Figure S2E). In summary, these findings
demonstrate that genetic inhibition of eIF4E phosphorylation
(which reduces translation of Mmp9 mRNA) is sufficient to
reverse the aberrant dendritic spine morphology, synaptic
mGluR-LTD deficits, and several core ASD-like phenotypes in
Fmr1/y mice.
Chronic Pharmacological Inhibition of eIF4E
Phosphorylation Reverses Excessive LTD and FXS-like
Phenotypes in Fmr1/y Mice
Cercosporamide is a potent inhibitor of Mnk1/Mnk2 kinases (Ko-
nicek et al., 2011) (Figure 5A). Cercosporamide has been tested
in preclinical models of lung and colon carcinomas, where it sub-
stantially reduced proliferation and survival of cancer cells (Koni-
cek et al., 2011). We first studied the effects of cercosporamide
on eIF4E phosphorylation in the brain. Following a single intra-
peritoneal injection of 20 mg/kg of cercosporamide in wild-
type mice, we detected a decrease in eIF4E phosphorylation
(25%), whereas a dose of 40 mg/kg led to an 50% decrease
(Figure S5C). Mass spectrometry analysis of brain tissue
revealed that cercosporamide was present in the brain, thus
demonstrating that it crosses the blood-brain barrier (Fig-
ure S5D). To assess the effect of chronic cercosporamide
treatment, we injectedmice daily for 5 days with various concen-
trations of cercosporamide and subjected the mice to the three-
chamber social interaction test. The 40 mg/kg 5 day regimen
impaired social approach behavior in WT mice, whereas the
20 mg/kg had no significant effect (Figure S5E). Importantly,
the cercosporamide dose response experiment in Eif4eki and
Mnkhet mice revealed that social approach behavior for both ge-
notypes was not affected by 40 mg/kg for 5 days, indicating that
at these concentrations (20–40 mg/kg) the effect of cercospora-
mide is mediated specifically via eIF4E phosphorylation (Fig-
ure S5F). We thus used the 20 mg/kg 5 day treatment as ‘‘sub-
threshold’’ and the 40 mg/kg as ‘‘above threshold.’’ Chronic
treatment with ‘‘subthreshold’’ cercosporamide concentration
reduces eIF4E phosphorylation and expression of Mmp-9 (Fig-
ures 5B and 5C).
Next, we tested whether pharmacological reduction of eIF4E
phosphorylation using chronic cercosporamide treatment nor-
malizes elevated general translation in Fmr1/y mice. To this
end, we prepared hippocampal slices from WT and in Fmr1/y
mice treated chronically with 20 mg/kg cercosporamide or
vehicle and measured de novo protein synthesis using puromy-
cin labeling. We detected a reversal by cercosporamide of the
increase in puromycin incorporation in slices from Fmr1/y
mice, but no significant effect in slices from WT mice
(Figure S5G).
Having established that cercosporamide crossed the blood-
brain barrier and reduced eIF4E phosphorylation, we treated
Fmr1/y mice and wild-type littermates with the subthreshold
dose of cercosporamide (20 mg/kg, 5 days; Figures 5A–5C).
First, we measured dihydroxyphenylglycine (DHPG)-induced
mGluR-LTD in CA1 hippocampal slices prepared from vehicle
and cercosporamide-treated animals. Cercosporamide-treated
Fmr1/y mice displayed a significant decrease in mGluR-LTD
(20%; Figures 5D and 5E), in comparison to vehicle-treated
Fmr1/y mice, whereas in wild-type mice the mGluR-LTD was
not affected by chronic cercosporamide treatment (Figures 5D
and 5E). One injection of cercosporamide (20 mg/kg) had no ef-
fect on DHPG-induced mGluR-LTD in Fmr1/y mice (Figures
S5H and S5I). Chronic cercosporamide treatment in Fmr1/y
mice achieved a complete reversal of several ASD-like behav-
iors, such as the preference for social novelty impairment
(Figure 5F; without affecting social approach behavior in the
three-chamber test [Figure S6A]), the aggressive behavior to-
ward a juvenile male (Figure 5G), the reduced sociability and
the occurrence of repetitive behaviors (exaggerated self-groom-
ing and reduced affiliation) during the interaction with a female
(Figure 5H), the hyperactivity behavior, as illustrated by the
increased number of light-dark transitions (Figure 5I) and cen-
ter-square occupancy in the open-field test (Figure 5J), and
finally the increased susceptibility to AGS (Figure 5K). Similarly
to the genetic rescue experiments, chronic cercosporamide
treatment did not lead to a significant improvement in the rotarod
(motor coordination) or novel object recognition tests in Fmr1/y
mice (Figures S6B and S6C). It also did not reverse the
Figure 5. Pharmacological Inhibition of eIF4E Phosphorylation Rescues FXS-like Phenotypes
(A) Cercosporamide (CERC.) is a selective potent inhibitor of Mnk1/Mnk2 and thus of phospho-eIF4E.
(B) Western blot of hippocampal lysates from WT and Fmr1/y mice injected with vehicle or treated chronically with cercosporamide (20 mg/kg). Representative
immunoblots are shown, probed with antibodies against the indicated proteins; b-actin was the loading control.
(C) Quantification of western blots from (B); n = 3, phopsho-eIF4E protein amounts are normalized to eIF4E and presented as percentage change relative to
vehicle. *p < 0.05 Student’s t test.
(D and E) Fmr1/y (Veh., n = 18; Cerc., n = 17) and WT (Veh., n = 14; Cerc., n = 10) mice were injected daily with cercosporamide (20 mg/kg) or vehicle for 5
consecutive days and 1 hr after the last injection hippocampal slices were prepared. Enhanced mGluR-LTD in Fmr1/y slices was normalized after chronic
treatment with cercosporamide. Scale bar, 5 ms and 1 mV; **p < 0.03, using one-way ANOVA followed by Bonferroni post hoc tests.
(F) Preference for social novelty three-chamber social interaction test, showing time spent in each chamber (LEFT) and time spent interacting with the novel social
stimulus (right; stranger 2; S2) or the previously encountered mouse (stranger 1; S1); C, center compartment.
(G) Social interaction with a juvenile male mouse test. Latency to attack and time spent in affiliation are measured for the indicated genotypes.
(H) Social interaction with a female mouse test. Time engaged in self-grooming and time spent in affiliation are depicted.
(I) Light-dark transition test. Number of transitions between the light and dark compartments is shown.
(J) Open-field exploration. Number of entries and time spent in the center square of an open field is measured.
(K) Audiogenic seizure frequency (% of animals having seizures). X marks resistance of WT mice to AGS.
For (F)–(K), n = 12 for each group; ***p < 0.001, *p < 0.05, two-way ANOVA with Bonferroni’s post hoc. See also Figures S5 and 6. Data are presented as mean ±
SEM (error bars).
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macroorchidism phenotype in Fmr1/y mice (Figure S6D). These
data constitute a pharmacological approach to selectively
reduce eIF4E phosphorylation, and, in conjunction with the ge-
netic rescue (Figure 4), bolster the important role of translational
control through eIF4E phosphorylation in rescuing core ASD-like
symptoms in Fmr1/y mice.
High-Dose Cercosporamide Impairs Social Approach
Behavior in WT but Not Mmp9/ Mice
We showed that translational control through phospho-eIF4E
primarily controls a subset of mRNAs (Furic et al., 2010), and in
the brain Mmp mRNAs are eIF4E key targets (Figures 3 and
S3). Taking into account our finding that MMP-9 overexpression
inmice induced a subset of phenotypes similar to Fmr1 knockout
mice (Figure 2), we hypothesized that Mmp-9, downstream of
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Figure 6. Mmp9 Is a Critical Target of Phos-
pho-eIF4E-Dependent Translation in Fmr1/y
Mice
(A) Mmp9 is translationally controlled by phospho-
eIF4E in FXS.
(B) Three-chamber social interaction test in WT or
Mmp9/ mice, injected with vehicle or a chronic
(5 days), ‘‘above-threshold’’ dose of cercospor-
amide (CERC.; 40 mg/kg). Time spent in each
chamber (left) and time spent sniffing each wire
cage (right), are shown; S1, stranger 1 (social
stimulus); C, center compartment; E, empty wire-
cage compartment (nonsocial stimulus).
(C) Preference for social novelty three-chamber
social interaction test in WT and Fmr1/y vehicle or
cercosporamide (20 mg/kg, 5 days) treated, and
simultaneously infused with recombinant pro or
active forms of Mmp9 (0.1 mg/ml, 2 ml per dose, two
times a day for 5 days). Time spent in each chamber
(LEFT) and time spent interacting with the novel
social stimulus (right; stranger 2; S2) or the previ-
ously encountered mouse (stranger 1; S1); C,
center compartment; i.c.v., intracerebroventricular
infusion. For (B) and (C), n = 10 for each group;
***p < 0.001, *p < 0.05, two-way ANOVA with
Bonferroni’s post hoc.
Data are presented as mean ± SEM (error bars).
phospho-eIF4E is a cardinal effector of
the Ras/MAPK/Mnk pathway in FXS (Fig-
ure 6A). To substantiate this claim,
we used Mmp9/ mice injected with
40 mg/kg cercosporamide (5 days). In
contrast to MMP9-Tg mice, Mmp9/
mice do not display deficits in social inter-
action, as measured by the three-cham-
ber social interaction test (Figure 6B).
The 40 mg/kg cercosporamide dose im-
pairs social approach behavior in WT
mice, as evidenced by the significantly
reduced interaction of the test mouse
with the social stimulus, and the signifi-
cantly reduced time spent in the social
stimulus compartment, in the three-cham-
ber test (Figure 6A). Remarkably, this dose had no significant
effect on the social interaction of Mmp9/ mice (Figure 6B).
Taken together, these data show that the effects of cercospora-
mide are mediated through Mmp9.
Recombinant Active MMP-9, but Not Pro-MMP-9,
Abrogates the Rescue of Social Behavior Deficits
by Cercosporamide in Fmr1/y Mice
To further establish the role ofMmp9 in Fmr1/y phenotypes, we
used recombinant, active MMP-9, which exhibits a profound
stimulatory effect on synaptic potentiation in CA1 (Bozdagi
et al., 2007). A single dose (0.1 mg/ml, 2 ml) of active but not inac-
tive pro-MMP-9 elicits an increase in potentiation in CA1 in vivo
(Bozdagi et al., 2007). We postulated that proteolytically active
MMP-9 infusion should occlude the rescue effects of chronic
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cercosporamide treatment in Fmr1/y mice. To this end, we
treated Fmr1/y mice with the chronic cercosporamide dose
(20 mg/kg) and simultaneously infused through cannulas active
or prorecombinant MMP-9 (two doses per day for 5 days,
0.1 mg/ml, 2 ml per dose). The mice were then tested in the pref-
erence for social novelty test. Infusion of active MMP-9 but not
of the proform was sufficient to block the rescue effects of
chronic cercosporamide treatment in Fmr1/y mice, as demon-
strated by the impaired preference for social novelty (Figure 6C).
These findings, together with the resistance ofMmp9/mice
to high-dose cercosporamide (Figure 6B), demonstrate that
translational control of Mmp9 mRNA through eIF4E phosphory-
lation is a regulatory mechanism in Fmr1/ymice, which could be
dysregulated in FXS.
DISCUSSION
Here, we showed that FXS patients display an increase in
MMP-9 protein and phospho-eIF4E levels in the brain (Figure 1).
Overexpression of MMP-9 in mice recapitulates major Fmr1/y
phenotypes (Figure 2). We also demonstrate that genetic inhibi-
tion of eIF4E phosphorylation reduces Mmp9 mRNA translation
(Figure 3). Likewise, genetic or pharmacological inhibition (cer-
cosporamide) of phospho-eIF4E rescues FXS-like phenotypes
in Fmr1/ymice (Figures 4 and 5). Thus, we postulate that a sub-
stantial fraction of the FXS-like phenotypes in Fmr1/y mice can
be explained by exaggerated phospho-eIF4E-dependentMmp9
mRNA translation.
Reversal of Exaggerated Translation in Fmr1/y Mice
by Phopsho-eIF4E Inhibition
A hallmark of Fmr1 deletion in mice is an increase in global pro-
tein synthesis, due to the absence of the translational ‘‘brake’’
that FMRP sets downstream of group 1 mGluRs (Bhattacharya
et al., 2012; Huber et al., 2001; Osterweil et al., 2013; Udagawa
et al., 2013). In Fmr1 knockout mice, mutation of the single phos-
phorylation site on eIF4E or happloinsufficiency of Mnk1 and
Mnk2 restored the general translation rates (Figure 3). However,
translation was not restored for all FMRP mRNA targets.
Restoring translation through normalizing eIF4E phosphorylation
primarily affected Mmps (Mmp9, Mmp2, Mmp3, Mmp7, and
Mmp24) and Dlg4 (PSD-95) (Figure S3), but not other FMRP
targets such as Camk2a (CamKIIa), Shanks, or Map1B. This is
similar to findings in Fmr1/S6K1 double-knockout mice, inas-
much as restoration of translation following ablation of S6K1
affects translation of most, but not all FMRP target mRNAs
(Bhattacharya et al., 2012). Thus, it is likely that, downstream
of group 1 mGluRs, different translation pathways such as 4E-
BPs, S6Ks, and phospho-eIF4E govern the translation of distinct
pools of neuronal mRNAs.
Genetic or Pharmacological Inhibition of eIF4E
Phosphorylation Restores Core FXS Behaviors
in Fmr1/y Mice
Excessive Ras/Erk signaling was reported in FXS patients (Wang
et al., 2012). We demonstrated increased phosphorylation of
eIF4E, which is a downstream target of the Ras/Erk signaling,
along with increased expression of MMP-9 in postmortem brain
samples (Figure 1). These findings in conjunction with increased
phosphorylation of eIF4E in FXS patients lymphocytes (Hoeffer
et al., 2012) and increased MMP-9 protein expression in amnio-
tic fluid of ASD mothers (Abdallah et al., 2012) raise the possibil-
ity that phospho-eIF4E regulation may be used to diagnose FXS
or ASD at earlier ages. Alanine mutation of the phospho-Ser209
site in eIF4E or deletion of one copy of Mnk1 and Mnk2 causes
a reduction in eIF4E phosphorylation (Figures 3 and 4). Similarly,
using cercosporamide, a Mnk1/Mnk2 inhibitor, we were able,
following chronic treatment, to reduce eIF4E phosphorylation
(Figure 5). In all cases, we achieved a rescue of the exaggerated
protein synthesis, the enhanced mGluR-LTD (without affecting
input/output and paired pulse ratio [Figures S5A and S5B]), the
immature CA1 dendritic spine morphology, and the FXS-like
behaviors (preference for social novelty, aspects of social inter-
action with juvenile males and females, light-dark transition,
open-field exploration, andaudiogenic seizures; Figures 4and5).
Cercosporamide Selectively Inhibits eIF4E
Phosphorylation and Reverses FXS-like Phenotypes
Our findings highlight cercosporamide as an inhibitor of eIF4E
phosphorylation in the brain (Figure 5; Figures S5 and S6), which
reverses a number of FXS-like phenotypes in adult Fmr1/ymice.
We showed that (1) a chronic subthreshold 20 mg/kg dose does
not affect social behavior in WT,Mnkhet, or Eif4eki mice and (2) a
chronic 40 mg/kg above-threshold dose impairs social interac-
tion in WT mice, but not in Mnkhet or Eif4eki (Figure S5). These
data indicate that our rescue experiments were carried out using
a concentration range where cercosporamide does not have any
off-target effects. Infusion of the active but not the latent form
of recombinant MMP-9 abrogated the rescue effect of chronic
cercosporamide injection in Fmr1/y mice. Thus, cercospora-
mide blocks Mnk kinase activity and selectively inhibits Mmp9
translation through reduced phosphorylation of eIF4E. These
data are consistent with previous work demonstrating that
lovastatin, a drug prescribed for treatment of high cholesterol, in-
hibits Ras-ERK1/2 upstream of phospho-eIF4E, corrects exces-
sive protein synthesis, and prevents epileptogenesis in Fmr1/y
mice (Osterweil et al., 2013).
eIF4E Phosphorylation and MMP-9 Overexpression as a
Potential Therapeutic Target in FXS/ASD, Downstream
of Group 1 mGluRs/Ras/ERK/Mnk
Increased amounts of MMP-9 (Figure 2), but not deletion of
Mmp9 (Figure 6), engender FXS/ASD-like phenotypes. The
lack of social deficits in Mmp9/ could be conceivably ex-
plained by homeostatic regulation of other members of the
MMP family. Mice overexpressing MMP-9 recapitulate several
FXS-like phenotypes, indicating that Mmp-9 is responsible for
a significant part of the Fmr1/y phenotype (Figure 2), which is
consistent with the increased translation of Mmp9 mRNA
observed in Fmr1/y mice (Figure 1). In particular, deletion of
Mmp9 in Fmr1/y mice, rescued synaptic, dendritic spine, and
behavioral deficits, further supporting the notion that Mmp-9 is
a master player in FXS phenotypes (Sidhu et al., 2014). Mmp-9
is a crucial target downstream of mGluRs/Mnk/phospho-
eIF4E, because it remodels the extracellular matrix by proteolyz-
ing some of its components, such as cell adhesion molecules,
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extracellular proteins, and potentially receptor subunits (Huntley,
2012). These activities ofMMP-9may intersect with those of pro-
teins implicated in ASD/FXS that are important for synaptic func-
tion and maturation. Thus, restoring normal Mmp9 translation
impacts the regulation of several Mmp-9 targets, which are
associated with FXS/ASD. Moreover, Mmp-9 is downstream of
group 1mGluRs, and it offers an appealing and selective avenue
for treatment that would exclude off-target upstream effects.
EXPERIMENTAL PROCEDURES
Knockin and Knockout Mice
Eif4eki (knockin Ser209Ala) mice were previously described (Furic et al., 2010).
Fmr1/y, Mmp9/, and Mnk1+//Mnk2+/ mice were on the C57Bl/6 back-
ground (Jackson Laboratories). All procedures were in compliance with the
Canadian Council on Animal Care guidelines and were approved by McGill
University, Universite´ de Montre´al, NCSR Demokritos Animal Care Commit-
tees and by the Eli Lilly and Company Institutional Animal Care and Use
Committee.
Polysome Profile Analysis and qRT-PCR
Polysome profile analysis and qRT-PCR were carried out as described (Gkog-
kas et al., 2013).
Western Blotting and Antibodies
All tissues were dissociated in RIPA buffer (unless otherwise specified). West-
ern blotting was previously described (Gkogkas et al., 2013).
Three-Chamber Social Approach and Preference for Social Novelty
Tests
A three-chamber arena was used to assess social approach and preference
for social novelty and was previously described (Gkogkas et al., 2013).
Self-Grooming Test
Mice were placed in a Plexiglas cage with fresh bedding and no nest or card-
board material. Self-grooming behavior was recorded for 10 min following an
initial 10 min habituation phase.
Social Interaction with Juvenile Male or Female Tests
Experimental and stimulus mice (juvenile 4-week-old C57Bl/6 male or 12-
week-old C57BL/6 female) were habituated to the experimental room and
the Plexiglas cage for 5 min. The unfamiliar stimulus mouse was then intro-
duced into the testing cage and left there for 5 min. Aggression, interaction
and affiliation, and self-grooming were scored.
Light-Dark Transition Test
The test apparatuswas composed of two chambers: a dark enclosed chamber
composed of wood (153 213 21 cm) and a larger chamber (303 213 21 cm)
with three clear Plexiglas walls and an open top. The two chambers are con-
nected by a small opening. Mice were placed into the ‘‘light’’ side and allowed
to explore freely for 10 min. An entry was defined as the mouse placing all 4 ft
into each zone.
Open-Field Exploration
Mice were placed into the center of a 40 3 40 3 30 cm chamber. Data were
collected in 2 min intervals for each mouse for 30 min. The number of entries
into the center square, which was used as a measure of anxiety-like behavior
was calculated.
Audiogenic Seizures
The test apparatus consisted of a Plexiglas cylinder (40 cm diameter and
60 cm deep) covered by a plate with a 120 dB alarm as described in Musumeci
et al. (2007).
Analysis of Neuronal Morphology by Golgi-Cox Staining
Rapid GolgiKit (FD NeuroTechnologies) was used for the staining procedure
according to the manufacturer’s instructions as described in Gkogkas et al.
(2013).
Electrophysiology
Electrophysiological experiments were performed as previously described
(Khoutorsky et al., 2013) with some modifications.
Measurement of De Novo Protein Synthesis
Transverse hippocampal slices (400 mm) were prepared from 5- to 6-week-old
mice and allowed to recover for at least 3 hr. Puromycin labeling was per-
formed as described previously (Hoeffer et al., 2011; Bhattacharya et al.,
2012) with some modifications.
Statistical Analysis
Experimenters were blinded to the genotype during testing and scoring. All
data are presented as mean ± SEM (error bars). Statistical significance was
set a priori at 0.05 (NS, nonsignificant). Details for tests used are provided in
the figure legends and Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.10.064.
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